

Erratum

Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers: Am J Cancer Res. 2023; 13(1): 161-175

Yongpeng Li^{1,2}, Lin Li^{2,3}, Haoyu Fu², Qing Yao², Lei Wang², Liguang Lou^{1,2,3}

¹School of Chinese Materia Media, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, Jiangsu, China; ²Shanghai Institute of Materia Media, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China; ³University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China

Received April 27, 2026; Accepted May 20, 2026; Epub October 15, 2026; Published October 30, 2026

In reviewing our submission, we identified some errors in **Figure 4**. Therefore, we provide the correct version to replace the wrong figures and reflect changes. We sincerely apologize for this oversight and any confusion it may have caused. The corrected **Figure 4** is shown below.

Address correspondence to: Lei Wang and Liguang Lou, Shanghai Institute of Materia Media, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China. Tel: +86-21-50806056; Fax: +86-21-50806056; E-mail: wanglei@simm.ac.cn (LW); lg lou@simm.ac.cn (LGL)

Synergistic effect of DS-8201 combined with DNA damage repair inhibitors




Figure 4. Combined inhibition of PARP and ATR synergistically enhances DS-8201-induced γ -H2AX foci formation. DNA damage was detected by immunofluorescence and visualized by confocal microscopy following treatment of NCI-N87 cells with DS-8201 (10 ng/mL), AZD2281 (3 μ M), and BAY1895344 (10 nM), alone or in combination, for 24 h.